Hidden Gems' Chris Waller Judges Scientific Thesis

Episode Summary

Executive Summary: The episode analyzes Judges Scientific, a UK-listed serial acquirer of niche scientific instrument businesses. Chris Waller argues the company’s hands-off, founder-friendly model has produced exceptional long-term returns and still has runway, but near-term results are pressured by Geotech, China, and US university spending freezes. The debate centers on acquisition durability, succession risk, and whether the stock’s valuation already reflects future compounding.

Main Topics: Judges Scientific business model (Priority: 5/5): Judges buys tiny, high-quality scientific instrument businesses at low multiples, keeps them autonomous, and relies on disciplined capital allocation rather than integration synergies. Why founders sell to Judges (Priority: 5/5): The company’s reputation for integrity and preserving businesses post-acquisition helps it win deals despite competing bids, especially versus PE or consolidators that promise synergies. Runway and scalability of acquisitions (Priority: 5/5): A major discussion focused on whether Judges can keep finding enough small deals to move the needle as the company grows, and whether larger acquisitions would dilute returns. Geotech acquisition and mixed record on larger deals (Priority: 4/5): Geotech, Judges’ largest acquisition, caused a profit setback when an annual expedition was delayed, raising concerns about scaling the model beyond small founder-led businesses. Macro and policy headwinds (Priority: 4/5): US higher-education spending cuts, uncertainty around NIH/grant funding, and prior China weakness have created a sharp near-term demand slowdown and a guidance cut. Management succession and capital allocation (Priority: 4/5): CEO David Ciccarelli’s age and eventual succession are key risks, but Waller argues the institutional culture and team buildout reduce dependence on any one person. Valuation, dividends, and incentives (Priority: 3/5): The stock trades at a premium multiple, but Waller believes the market can still justify it if growth continues; the episode also debates the dividend as suboptimal capital allocation for a compounder.

Key Arguments: Judges Scientific has historically compounded capital at roughly 20%+ annually by buying niche scientific instrument businesses at about 5-6x EBIT and leaving them operationally independent. The company’s moat is its reputation: after 20 years and 25 acquisitions, founders trust Judges not to retrade, consolidate, or damage culture post-close. Small acquisitions remain viable because the target universe is still large and management bandwidth has expanded, including additional team members and early platform-building within acquired businesses. Concerns about scaling are valid, but evidence from Halma and from Judges’ own successful larger deals suggests diminishing returns have not yet become binding at current revenue scale. Geotech’s problems were largely timing-related: a delayed annual expedition temporarily crushed earnings, but the underlying business still fits Judges’ niche, high-moat strategy. Near-term growth is impaired by U.S. university funding uncertainty; the market is treating the spending freeze as a near-100% cut, though some normalization should occur as uncertainty fades. Succession is the biggest structural risk, but Waller argues the company’s acquisition discipline is embedded in the organization and not solely dependent on the founder-CEO. A dividend makes little strategic sense for a serial compounder, but UK income-investor norms and management compensation explain why it persists. The current valuation can still work if Judges compounds earnings at a high-teens/20%-ish rate, but multiple compression would materially hurt returns.

Data Points: Market capitalization: ~£400 million - Judges Scientific’s approximate UK market value at the time of discussion. Long-term return on incremental capital: ~20% per annum - Chris Waller’s estimate of Judges’ incremental capital returns over 20 years. Stock return: ~25% per annum - Approximate long-term shareholder return cited during the discussion. Return on tangible capital: ~40% - Operating quality metric mentioned for the acquired businesses. Organic EBIT growth: ~9% - Historical organic growth rate cited for Judges’ businesses. Acquisition price multiple: ~5x EBIT on average; ~6x weighted average - Average price paid for acquisitions, emphasizing disciplined buying. Acquisition size: ~£5 million to £10 million deals - Typical size of the private businesses Judges acquires. Revenue mix: ~1/3 US, 1/3 Europe, 1/3 rest of world - Geographic sales distribution described by Waller. Stock drawdown: ~50% below peak - Judges’ share price decline over roughly 18 months due to headwinds. Geotech acquisition size: >£100 million including earn-out - Judges’ largest acquisition, far larger than its average deal size. Geotech share of free cash flow: ~20% - Geotech’s current contribution to Judges’ free cash flow. Annual expedition frequency: 1 per year - Geotech’s key vessel-based expedition activity that was delayed, not canceled. US college spending: Near complete halt since March - A major reason for the company’s recent guidance cut. EPS guidance cut: ~10% to 22% - Management reduced earnings guidance in the July trading update. Current share price: ~£60 - Referenced during the valuation discussion. Diluted earnings target in option grant: 5% EPS growth over 3 years - Management incentive package discussed by the hosts. Prior option grant target: 10% CAGR over 3 years - Earlier management incentive hurdle noted in the transcript. Founder ownership leverage: ~200x base salary / ~100x stock value vs pay - Illustrates the founder’s strong alignment and low salary dependence. CEO age: 76 - Central to the succession-risk discussion. COO ownership: ~20x base salary - Used to show incentive alignment among senior management. Revenue threshold in Halma comparison: <£500 million - Historical point where Halma’s acquisition returns began to diminish more materially. Judges revenue today: ~£130 million - Used to argue that Judges is still below the scale where acquisition returns should compress significantly. Current annual free cash flow: ~£20 million - Used to frame the company’s acquisition capacity over the next few years. Expected acquisition spend over next 3 years: ~£80 million - Rough estimate of capital available for acquisitions.

Pivotal Quotes: "This is a UK-listed 400 million pound market cap serial acquirer. It buys scientific instrument businesses." — Chris Waller: Core description of Judges Scientific’s business model. "The reason they sold to judges was because they’re very hands-off post-acquisition." — Chris Waller: Explains the founder-friendly acquisition advantage. "I think the punchline is: I think they should not be paying a dividend." — Chris Waller: His view on capital allocation for a high-return compounder.

Implications: Judges Scientific remains a high-quality compounder, but the thesis hinges on whether its founder-friendly acquisition engine and succession plan can outlast current macro headwinds and preserve returns as the company scales.